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Abstract: Growing demands on a suitable formulation method that ensures the stability of the active compound coupled 
with the limitations of current methods (milling, lyophilization, spray drying, and freeze spray drying) has brought wide 
attention to supercritical fluid (SCF) technology. Advantages of using the SCF technology comprise its high abilities, 
adaptability in providing alternative processing methods, high compressibility and diffusivity of the supercritical fluid, ca-
pability as an alternative for conventional organic solvents, and the option to attain different processing parameters which 
would be otherwise difficult to conduct with traditional methods. This review proposes to present an up-to-date outlook on 
dry powder pulmonary formulations of macromolecules using SCF technology.  
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1. INTRODUCTION 
 Over the past two decades a rapid growth of innovative 
technologies for producing novel therapeutic agents has 
arisen. This growth has mostly been initiated by the discov-
ery of new therapeutic agents, such as macromolecules, to-
gether with an increased understanding and knowledge of 
pathophysiology [1]. Consequently, novel macromolecules 
(also known as biotechnology-derived pharmaceuticals, bio-
therapeutics, or biological drugs and include recombinant 
therapeutic proteins, monoclonal antibody based products 
and nucleic acid-based medicinal products) can now be pro-
duced with preferential selectivity for definite targets [1, 2]. 
To date many macromolecule based drugs are in clinical 
trials or at approval phase (Table 1) [3]. Over the past decade 
pharmaceutical research and development has been focused 
on developing macromolecules for treatment of many dis-
eases, and are preferred due to their greater selectivity; lower 
disruption of normal biological processes; effective substitu-
tional therapy in mutated or deleted normal protein and less 
clinical development time in addition to a shorter FDA ap-
proval period [4,5]. 
 However, most of these macromolecules must be admin-
istered repeatedly using an invasive manner to reach a thera-
peutic concentration, even though these procedures would be 
painful to the patients [6-8]. As an alternative to repeated 
injection, pulmonary inhalation could enhance macromole-
cule administration because it is a non-invasive technique for 
local and systemic drug delivery. The lungs own many fa-
vorable features, including large surface area for absorption, 
highly vasculatures, thin epithelium in the alveolar tissue and 
short path of gas–blood exchange movement [8].  
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However, formulating macromolecules into suitable pulmo-
nary delivery systems remains a challenge.  
 A variety of micro/nanoparticulate systems such as 
polymer based micro/nanoparticles, liposomes and solid lipid 
micro/nanoparticles have been used for the encapsulation of 
macromolecules serving specific therapeutic purposes such 
as controlled release or targeted drug delivery. Major con-
cerns on the formulation method of macromolecules must be 
addressed when dealing with these molecules [7]. The stabil-
ity and biological activity of macromolecules are extensively 
dependent on their entire structures, and can be easily altered 
by physical means (e.g. denaturation, adsorption, or nonco-
valent aggregation) or chemical means (e.g. oxidation, 
deamidation, or peptide cleavage). The impact of modifica-
tions can be very complicated (losses in therapeutic activity, 
changes in absorption, biodistribution, elimination, toxicity 
and immunogenecity). In addition, these intact structures are 
important characteristics which have impact on the physico-
chemical properties of the final therapeutic products, espe-
cially in the case of pulmonary drug delivery that require 
careful manipulation of the particle size, shape, density, and 
surface properties (Table 2). Many different routes are em-
ployed to achieve solid-state formulations, including milling, 
freeze drying (lyophilization), spray drying (SD), and spray–
freeze drying (SFD) (Table 3). 
 Growing demands on a suitable formulation method that 
ensures the stability of the active compound coupled with the 
limitations of current methods (milling, lyophilization, spray 
drying, and freeze spray drying) brought wide attention to 
supercritical fluid (SCF) technology [2]. SCF are gases and 
liquids above their critical pressure (Pc) and critical tempera-
ture (Tc), and under these conditions, the molecules exhibit 
the flow, polarity, and solvency properties common of liq-
uids but have the diffusion and reactivity characteristics of 
gases. SCF technique can be performed using carbon dioxide 
(CO2), water, propane, acetone, nitrous oxide (N2O),
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Table 1. Examples of Therapeutic Macromolecules being Investigated for Systemic Delivery via the Pulmonary Route 
Type Active Agent Disease Ref. 
Erythropoeitin Anaemia [15] 
Insulin Diabetes [15] 
Parathyroid hormone Osteoporosis [14, 15] 
Cetrorelix LH-RH antagonist [15] 
Follicle stimulating hormone Fertility treatment [15] 
Hormone 
LH-RH analogues Endometriosis, prostate cancer [15] 
Sargramostim Sarcoma [15] 
Growth factor 
Growth hormone releasing factor Pituitary dwarfism [14] 
Blood derivative Immunoglobulin Trigger/modulate immune response [15] 
Interferon-beta Interferon Multiple sclerosis [14, 15] 
Calcitonin-salmon Osteoporosis [14, 15] 
Heparin Inhibit thrombosis [14, 15] Natural extract 
Cyclosporine immunosuppression [15] 
Recombinant protein Human recombinant F.IX Hemophilia B [15] 
HBsAg Hepatitis B [16] 
P30B2, (NANP)6P2P30 Malaria [16] 
SPf66 Malaria [16] 
Hemagglutinin Influenza [16] 
Mtb8.4 peptide Tuberculosis [16] 
HLA-A*0201 plasmid Tuberculosis [16] 
Diphtheria toxoid Diphtheria [16] 
Tetanus toxoid Tetanus [16] 
Vaccine 
Formalin- inactived rotovirus Rotavirus [16] 
 
Table 2. Product Parameters and Pharmaceutical Considerations in Drug Product Design 
Parameter Importance/Effect Ref. 
Particle size and distribution 
Precise targeting 
Content uniformity 
Rates of dissolution, 
Rates of release, 
Dose delivery 
[18-20] 
Particle shape (morphology) 
Flow property 
Dispersibility 
[21] 
Particle density 
Flow property 
Dispersibility 
[22] 
Particle surface charge 
Optimal surface properties of particles must be obtained to prevent particles agglomeration 
Flow property 
Dispersibility 
Precise targeting 
[16, 21, 23] 
Crystal form Crystal form influences all steps of the development from discovery to marketing [10] 
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Table 3. Common Methods for Formulations of Macromolecules 
Method Description Disadvantages Excipients Ref. 
Jet Milling 
Bulk particles are introduced into the milling chamber. Air or 
nitrogen, fed through nozzles at high pressure, accelerates the 
solid particles to sonic velocities. The particles collide and 
fracture. While flying around the mill, larger particles are sub-
jected to higher centrifugal forces and are forced to the outer 
perimeter of the chamber. Small particles exit the mill through 
the central discharge stream 
Broad particle size 
Physical/chemical degradation 
e.g. trehalose [21] 
Freeze drying 
(Lyophilization) 
The formulation is frozen and the bulk water is removed by 
sublimation. The resulting cake is composed of the protein, any 
nonvolatile excipients, and a small amount of residual water 
tightly associated with the protein 
Time consuming 
Broad particle size distribution 
e.g. trehalose, 
inulin,  dextran 
[6, 11] 
Spray drying 
Uses atomization to form microdispersed droplets. The water in 
these droplets quickly evaporates when passed through a 
stream of hot gas, resulting in the formation of a fine powder of 
microparticles containing protein and excipients 
Degradation 
Low process efficacy 
Time consuming 
e.g. leucine, 
lactose, treha-
lose, dipamitoyl-
phosphatidylcho-
line (DPPC), 
albumin 
[8, 11, 22, 
24, 25] 
Spray-freeze 
drying 
The microdispersed liquid particles are generated through the 
jet nozzle in the absence of heat, then collected and frozen in 
liquid nitrogen before sublimation occurs. The frozen particles 
are then lyophilized 
Degradation 
Low process efficacy 
Time consuming 
e.g. inulin, treha-
lose, manitol 
[6, 8, 21, 
24] 
Supercritical 
Fluid 
SCF are gases and liquids above their critical pressure and 
critical temperature. SCF technique can be performed using 
carbon dioxide (CO2), water, propane, acetone, nitrous oxide 
(N2O), trifluoromethane, chlorodifluoromethane, diethyl ether, 
water, or CO2 with ethanol 
Solubility of molecules in solvent 
Degradation 
Particle size control 
Residue of organic solvent 
Scale up of this process is re-
stricted by particle aggregation 
and nozzle blockage due to rapid 
expansion cooling. 
e.g. sucrose, 
trehalose,  
manitol 
[2, 8, 11, 
13] 
 
trifluoromethane, chlorodifluoromethane, diethyl ether, wa-
ter, or CO2 with ethanol [13]. In addition SCF possess sev-
eral fundamental advantages as solvents and/or anti-solvents 
for processing heat-labile solutes at low temperature. For 
example, supercritical CO2 is a good solvent for water-
insoluble as well as water-soluble compounds under suitable 
low critical conditions (Tc = 31.2 °C, Pc = 7.4 MPa) [8]. In 
addition, compressed CO2 is accessible in ample proportions 
with a higher degree of purity [9]. Moreover, CO2 is non-
toxic, nonflammable, and inexpensive [8]. Therefore, super-
critical CO2 has potential as an alternative for conventional 
organic solvents used in solvent-based processes for forming 
solid dosage forms. Furthermore, the general consideration 
of SCF as a “green” substitute has become very significant 
as the harmful effects of residual organic solvents, from both 
a processing and environmental point of view, have been 
known, and in addition, the regulatory specifications for the 
utilization and residual amounts of organic solvents in the 
final pharmaceutical product become more stringent [10]. 
 There are two major principles based on SCF. The first 
process utilizes supercritical fluids as a solvent. The Rapid 
Expansion of a Supercritical Solution (RESS) process is the 
method that represents this first principle. Initially the solute 
must dissolve in a SCF followed by sudden decompression, 
after which the solution is rapidly expanded at low pressure 
by passing through an orifice. The restrictions facing appli-
cation of RESS for macromolecules formulations include: it 
is restricted to molecules that are soluble in SCF CO2, rela-
tively high temperature required for the rapid expansion 
(typical temperature of 40 ºC) which can destroy proteins, 
lacking control of particle size, and scale up of this process is 
restricted by particle aggregation and nozzle blockage due to 
rapid expansion cooling [8].  
 The second process involves the solute being insoluble in 
SCF and hence utilizes SCF as an antisolvent. Many macro-
molecules which are suitable as therapeutic agents are 
slightly soluble in SCF and have high solubility in water. 
These processes use SCF as an antisolvent where a solute is 
dissolved in an organic solvent then precipitated by SCF. 
Precipitation develops when the SCF is absorbed by the or-
ganic solvent followed by expansion of the liquid phase and 
decreases in the solvent power leading to particle formation. 
The Gas Anti-Solvent (GAS), Aerosol Solvent Extraction 
System (ASES), Supercritical Fluid Antisolvent (SAS), Pre-
cipitation with Compressed Antisolvent (PCA), Solution 
Enhanced Dispersion by Supercritical Fluids (SEDS), and 
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supercritical fluid extraction of emulsion (SFEE) are the 
processes that exemplify this second group Fig. (1). The 
main disadvantage of the second process that applies SCF as 
antisolvent is the difficulty to remove the residual organic 
solvent completely [8]. 
 Thorough discussions of differences in the above tech-
niques have been recently published elsewhere [8-13]. This 
review proposes to present an up-to-date outlook on the pro-
gression of dry powder formulations for inhalation of mac-
romolecules using SCF techniques, covering its challenges, 
possibilities and recent developments.  
2. SUPERCRITICAL FLUID APPLICATIONS IN 
PREPARATION OF MACROMOLECULES FOR DRY 
POWDER INHALATION 
 Unlike conventional methods of particle formation such 
as milling, lyophilization, spray-drying, and freeze-spray 
drying, where large particles are reduced to the intended size, 
SCF technology includes developing the particles in a con-
trolled approach to achieve the intended size. Therefore the 
negative effect of the energy transmitted to the system such 
as denaturation of protein to produce the desired size can be 
avoided. Ideally, the particles once formed must not be sub-
jected to further treatment and this property makes SCF 
technology suitable to produce macromolecules in their na-
tive pure state and/or encapsulating these agents [13].  
 Advantages of using the SCF technology comprise its 
high abilities, adaptability in providing alternative processing 
methods, the high compressibility and diffusivity of SCF, 
capability as an alternative for conventional organic solvents, 
and the ability to reach different processing parameters (such 
as pressure and the rate of solvent evaporation) which would 
otherwise be difficult to conduct with conventional methods 
[10]. 
2.1. Encapsulation of Insulin 
 SCF have unique properties as mentioned above that 
makes them applicable for various processing methods such 
as particle formation and extractions. Recently, a significant 
interest in SCF technology has been revealed in an attempt to 
find other preferable approaches of insulin processing. 
 Todo et al. [26] examined the absorption of insulin dry 
powders processed with mannitol (carrier) and citric acid (an 
absorption enhancer) by the SCF process known as solution 
enhanced dispersion by supercritical fluids (SEDS) with that 
prepared by spray drying (SD) technique. In this investiga-
tion insulin powder was precipitated by dispersing the insu-
lin aqueous solutions through V-type nozzles into supercriti-
cal CO2/ethanol/water ternary system. Water feed rate, liquid 
CO2 feed rate, ethanol feed rate, pressure, and temperature 
were 0.035 mL/min, 5.7 g/min, 0.665 mL/min, 15 MPa, and 
35 ºC, respectively. These operating conditions enabled the 
water to be miscible with the non-polar CO2. A manual in-
jector was used to introduce aqueous 0.25 % insulin solution 
with 0.2% citric acid and 5.0 % mannitol into the water 
stream. For dry powders (0.25 % insulin solutions containing 
5 % mannitol and 0.20 % citric acid) prepared by SD tech-
nique the following standard operating parameters were 
used: an inlet temperature of 90 ºC, a drying air flow rate of 
0.75 m
3
/min, a solution feed rate of 5 mL/min, and an atom-
izing air pressure of 100 kPa. The authors found that insulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic diagrams of various particle-formation processes using supercritical fluid technology. RESS: Rapid Expansion of a Su-
percritical Solution, GAS: Gas Anti-Solvent, ASES: Aerosol Solvent Extraction System, SAS: Supercritical Fluid Antisolvent, PCA: Precipi-
tation with Compressed Antisolvent, SEDS: Solution Enhanced Dispersion by Supercritical Fluids, and SFEE: supercritical fluid extraction 
of emulsion. 
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powder prepared by the SCF method showed enhanced aero-
solisation efficiency at 28 L/min using an Andersen Cascade 
Impactor in comparison with insulin powder prepared by the 
SD method. For example, SCF insulin powders had the 
greatest quantity of powder retrieved from stages 2–7 and a 
mass median aerodynamic diameter of 3.2 ?m with 
respirable fraction of 47.6 %. The hypoglycemic effect of 
insulin powder processed by SCF after intratracheal applica-
tion was higher than that produced by SD. In addition, they 
found that SCF technique provided the largest yield of insu-
lin powder (>80 %) although it was on a laboratory scale 
production. These results demonstrated that the SCF process 
would be beneficial to prepare inhalable insulin powder.  
 Amidi et al. [27] demonstrated that PCA-type SCF tech-
nology is an appropriate method to manufacture inhalable 
insulin-loaded microparticles with specific particle properties 
and retained structure of insulin. The authors used N-
trimethyl chitosan (TMC), as a mucoadhesive absorption 
enhancer, and dextran as carriers for insulin, and prepared 
two formulations of 10 % (w/w) of insulin/TMC or insulin/ 
dextran. The particles were formed by spraying an acidic 
water/dimethyl sulfoxide (DMSO) solution of insulin and 
polymer within supercritical CO2. The flow rates of polymer-
insulin solution and CO2 were 4.5 mL/min and 333 g/min, 
respectively. The pressure and temperature were maintained 
at 110 bar and 40 °C. The mass median aerodynamic diame-
ter was 4 ?m and the percentages of the emitted dose were 
62 and 67 % for insulin/TMC and insulin/dextran respec-
tively. The water content of the particles was 4 % (w/w), and 
neither crumpled nor agglomerated after formation and stor-
age. The intact structure of insulin in the freshly formulated 
dried insulin powders were monitored by circular dichroism 
spectroscopy, which indicated the secondary and tertiary 
structures of insulin was retained in all preparations. Fur-
thermore, at the end of one-year storage at 4 °C, the particle 
properties were preserved and the insulin structure almost 
retained in the TMC powders.  
 Kim et al. [28] compared micronized insulin using man-
nitol as a stabilizer alone or with the addition of trehalose as 
a second stabilizer using a process known as aerosol solvent 
extraction system (ASES) SCF technology. They injected 
co-currently the solution of insulin/mannitol (15/85 wt.%) 
with or without 10 and 15 wt.% trehalose with the CO2 into 
the precipitation vessel using the solvent, N,N-
dimethylformamide (DMF) at 35 °C, 180 bar, 8 mg/mL solu-
tion concentration, and 5 ml/min solution flow rate. Results 
indicated that when trehalose was used as a second stabilizer, 
the particles were almost uniform, more spherical, less adhe-
sive, and less aggregated in air flow, in comparison to insu-
lin mannitol particles alone. The mass median aerodynamic 
diameter of the insulin/mannitol particles was ~5 ?m and of 
the insulin/mannitol/trehalose particles was ~2.32 μm, 
which are appropriate for inhalable dosage from. In vitro 
aerosolisation deposition test conducted with a micro-orifice 
uniform deposit impactor (MOUDI-II™Impactor) at 30 
L/min revealed 69 % by weight of the insulin/mannitol and 
41 % by weight of the insulin/manitol/trehalose particles was 
deposited on stages 3, 4, 5 and 6. This study showed the 
ASES process was able to retain the secondary structures of 
insulin in both insulin/mannitol and insulin/manitol/trehalose 
particles. 
2.2. Gene Powders 
 Polymer based non-viral gene delivery systems have 
been shown to offer protection from nuclease degradation, 
increased plasmid DNA (pDNA) uptake and sustained dura-
tion of pDNA action [29]. These gene delivery systems can 
be prepared from biologically compatible and degradable 
polymers e.g. poly (d,l-lactic-co-glycolic) acid (PLGA). The 
effectiveness of gene therapeutic systems depends on the 
ability of such system to deliver nucleic acid into the target 
cells. Gene dry powders are anticipated to have further ad-
vantage of prolonged shelf life of the preparation [29]. 
 Okamoto et al. [29] compared stability of a chitosan–
pDNA complex powder processed by a SEDS-type SCF 
technique and gene solution alone for inhalation. They pre-
cipitated the gene powder by dispersing an aqueous chito-
san–pDNA complex solution with mannitol into the stream 
of a SCF CO2/ethanol admixture. In the mixing column, the 
CO2 was admixed with ethanol at a flow rate of 5.7 g/min 
and 0.665 mL/min respectively. Using these operating condi-
tions resulted in complete miscibility of ethanol, water, and 
CO2. The admixture was dispersed into the particle forma-
tion vessel at 35 ºC and 15 MPa using one end of the V-
shaped nozzle, while the other end of the V-shaped nozzle 
was used to disperse water at a flow rate of 0.035 mL/min. 
The aqueous chitosan–pDNA complex solution (0.4 mL) 
was manually injected into the water stream and the dry 
powder was collected from the depressurized vessel. This 
procedure resulted in powder yields of ~80 % and aerody-
namic particle sizes of ~3 ?m, which was appropriate for 
pulmonary delivery. Scanning electron microscopy examina-
tion revealed the powders to have rectangular shape. Gene 
integrity and transfection potency were determined by elec-
trophoresis and in vivo pulmonary transfection test in mice. 
The SCF technique minimized the supercoiled DNA during 
the formulation processing; although, the reduction in the 
remaining supercoiled and open circular DNA in the pow-
ders during storage was more prolonged than in solutions. As 
a result, the powders generated using SEDS had increased 
transfection potency in comparison to the gene solutions for 
the same quantity of DNA.  
 Mayo et al. [30] developed a SCF extraction of emul-
sions (SFEE) technique based on CO2 for formulating 
nanoparticles having high plasmid (pFlt23K, an anti-
angiogenic pDNA capable of inhibiting vascular endothelial 
growth factor (VEGF) secretion) loading and loading effi-
ciency. First they prepared a lipophilic phase by dissolving 
PLGA into ethyl acetate and the inner aqueous phase com-
posed of pFlt23K Tris-EDTA buffer. The aqueous phase was 
sonicated for 1 min (15W) with the lipophilic phase to obtain 
a 1° emulsion (w/o). The outer aqueous phase consisted of 
0.5 % (w/v) polyvinyl alcohol (PVA) saturated with ethyl 
acetate. The 1° emulsion was further sonicated with the outer 
aqueous phase for 3 min to obtain the 2° emulsion (w/o/w). 
The emulsion extraction and particle production was per-
formed using coaxial SFEE apparatus consisting of a cylin-
drical pressure vessel, placed in a temperature controlled 
water bath at 45 °C. Supercritical CO2 was injected via a 
syringe pump to the base of this vessel. The emulsion was 
introduced counter currently by means of a 100 ?m capillary 
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tube within a 1/16” stainless steel high pressure tubing at the 
top of the vessel, permiting CO2 to flow continually from the 
vessel. During the process the pressure and flow rate of the 
emulsion were kept at 8 MPa and 0.4 ml/ min, respectively. 
Results revealed spherical particles with smooth surface and 
280 nm in diameter. In addition, a high loading of pFlt23K 
(19.7 %, w/w) and high encapsulation efficiency (>98 %) 
was achieved, while a low residual solvents (<50 ppm), at-
tributed to rapid particle formation due to successful solvent 
removal afforded by the SFEE technique. In vitro transfec-
tion of pFlt23K-PLGA nanoparticles were able to signifi-
cantly reduce secreted VEGF from human lung alveolar 
epithelial cells (A549) with normoxic and hypoxic status, 
with no cytotoxicty detected. 
2.3. Vaccination 
 Recently immunization by inhalation has been investi-
gated as a substituent for parenteral vaccination. Vaccines 
delivered via the lung route can initiate both systemic and 
local immune responses due to the presence of extensive 
dendritic cells and macrophages lining the respiratory epithe-
lium. 
 Amidi et al. [31] examined the potential of N-Trimethyl 
chitosan (TMC) and dextran microparticles for pulmonary 
delivery of diphtheria toxoid (DT). DT-loaded microparticles 
were formulated by spraying an aqueous solution of 
DT/dextran (w/w) or DT/TMC into supercritical CO2 and 
ethanol using SEDS type SCF technology. When the operat-
ing temperature (38 ºC) and pressure (100 bar) was achieved, 
CO2 and ethanol were completely miscible forming a single 
supercritical phase. The ethanol/CO2 mixture was immedi-
ately introduced via a concentric coaxial two-fluid nozzle 
and sprayed into the vessel for 5 min. This was subsequently 
followed by pumping the aqueous polymer-DT solution into 
the T-mixer at a flow rate of 0.5 ml/min using two syringe 
pumps. This was mixed with SCF-CO2 (367 g/min) and 
ethanol (25 ml/min) and fed into the precipitation vessel 
through the concentric coaxial two-fluid nozzle. Smooth 
spherical particles were produced with median volume di-
ameter of ~3 ?m and the fine particle mass fractions less 
than 5 ?m, as revealed by cascade impactor analysis at 30 
L/min, were 35 % for the dextran and 56 % for the TMC 
formulations. 
 This study demonstrated that the generated powders had 
a significant mass fraction of particles less than 5 ?m, suit-
able for inhalation. In addition, this investigation revealed 
that TMC microparticles were a potent pulmonary delivery 
system for DT antigen. Pulmonary immunization with DT-
TMC microparticles containing 2 or 10 Lf of DT produced a 
strong immune response as manifested by the production of 
IgM, IgG, IgG subclasses (IgG1 and IgG2) antibodies simi-
lar to or significantly greater than those gained after subcuta-
neous application of alum-adsorbed DT (2 Lf). In addition, 
the IgG2/IgG1 ratio after pulmonary immunization with DT-
TMC microparticles was significantly greater in comparison 
with subcutaneous administered alum-adsorbed DT. While 
pulmonary administrations of DT-dextran particles produced 
a very poor immune response.  
 
3. CONCLUSION 
 There has been great progress in supercritical CO2 tech-
niques to increase performance of macromolecules without 
losing the biological activity of these sensitive molecules. 
However, there are still possibilities for optimizing process-
ing parameters, such as temperature, pressure, flow rates, 
and concentration of ingredients. In addition, processing of 
therapeutic macromolecules with supercritical CO2 permit a 
wide range of macromolecules to be processed, and in the 
future it is expected that SCF techniques will provide a more 
favorable alternative to producing formulations encapsulat-
ing macromolecules.  
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